巨噬细胞M2标志物CD163和MRC1在急性髓性白血病中的预

巨噬细胞M2标志物CD163和MRC1在急性髓性白血病中的预后分析

http://www.100md.com 2025年6月24日医学信息 2025年第7期

DOI：10.3969/j.issn.1006-1959.2025.07.001 文章编号：1006-1959(2025)07-0001-09

Abstract：ObectiTvestigaetfofteexprsiooftmoasoatedmacoM(-TAs)markersCDndote survivalandprognosisofacutemyeloidleukemia(AML)MethodsPan-canceranalysisofCD163andMRC1wasperformedbyTCGAand UALCAN.TAEplerdealeapdl prognosisfCD16andMRClinAMLTheSCHdatabasewasusedtoaalyzeCD163andMRC1atthesinglecellevel.ResultsTheepreion fMRC1wasoeglatedinosortissusndteexpressoofC63inotissssgertantatintsss

BysearchingCGAGEUNKaplaeeroedlcabssdhathali withhighexpressonofC16adC1wasshorethanthatoflwexpressongoupichwasaigiskfactorandeieeas statistically significant

.InthesinglecelldatasetAML_GSE116256，it was found thatCD163 was mainlyexpressed inmononuclear macropgespdoseldaltdsu TAMswasverifdyellplaleatioduoeseCocusioompadihalttrolstitsa highexpressofCD163andMRC1，andatientswithghM2TAMsinfiltrtionaveaoorprogosisCD63ndMRC1wereprelarily demonstrated as potential prognostic indicators in AML. ......

百拇医药网 http://www.100md.com/html/paper/1006-1959B/2025/07/020.htm

您现在查看是摘要页，全文长 17383 字符。